CCN2 and breast cancer: Silencing of ATF2 in TAMRs lead to downregulation of ABL1, CDK4, CTGF, DNMT1, PARP3 and VEGFA that have been linked to endocrine resistance and poor prognosis in BC, and there are several drugs available targeting these genes (FDA approved or in clinical trials, supplementary file 3).